Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1026 in Chinese Participants With Relapsed or Refractory Hematologic Malignancies
NCT05347225Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nemtabrutinib in B-cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 1 more, sponsored by Merck & Co. Primary endpoints: Number of Participants who Experience Adverse Events, Number of Participants Discontinuing Study Treatment due to AEs and 4 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
nemtabrutinib
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT05347225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347225.